Description
An agonist of GPR55 (EC50 = 13 nM in a GTPγS binding assay); selective for GPR55 over CB1 and CB1 receptors (EC50s = >30 µM for both in GTPγS binding assays); reduces growth of Mz-ChA-1, HuCCT-1, CC-LP-1, and SG231 cholangiocarcinoma cells at 50 µM; reduces tumor growth in a Mz-ChA-1 mouse xenograft model at 10 mg/kg per day; increases food intake and fat mass in rats in a GPR55-independent manner; reduces movement-induced firing of nociceptive C fibers in a rat model of inflammatory joint pain
Formal name: 5-methyl-4-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-1,3-benzenediol
Synonyms: Abn-CBDO|Abnormal Cannabidiorcin|Abnormal Cannabidiorcinol|Abnormal Cannabiorcodiol
Molecular weight: 258.4
CAS: 317321-41-8
Purity: ≥98%
Formulation: A solution in methyl acetate
Product Type|Biochemicals|Receptor Pharmacology|Agonists||Research Area|Cancer||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Obesity||Research Area|Immunology & Inflammation||Research Area|Neuroscience|Behavioral Neuroscience|Food Intake||Research Area|Neuroscience|Cannabinoid Research||Research Area|Neuroscience|Pain Research